Effects of Vaginal vs. Oral Progesterone Supplementation Before Embryo Transfer on Live Birth Rates and Levels: A Randomized Trial.

Abstract

The increase in frozen embryo transfers is a consequence of advances in embryo vitrification and the implementation of genetic screening of embryos. There is debate over the best progesterone administration route in substituted cycles and the relationship between progesterone levels on embryo transfer day and reproductive outcomes. This trial aimed to compare the clinical results of different progesterone supplementation schedules before embryo transfer and assess the relationship between plasmatic progesterone levels on transfer day and clinical outcomes. In a prospective, randomized, controlled study, 500 patients were randomly divided into two groups based on the progesterone administration route (oral or vaginal) prior to embryo transfer. Progesterone levels were measured on embryo transfer day (PP1) and B-HCG determination (PP2). The primary endpoint was the live birth rate according to different progesterone schedules and progesterone levels on transfer day. Despite higher plasmatic progesterone levels with oral administration compared to the vaginal route, there were no significant differences in clinical pregnancy (50.20% vs. 47.37%), live birth (43.67% vs. 40.89%), or miscarriage rates (13.33% vs. 6.48%). Progesterone levels on transfer day were significantly higher in patients with ongoing pregnancies (24.96±1.00 ng/ml) compared to those without (18.02±1.07 ng/ml) (p=0.001). Among patients with positive pregnancy tests, the differences between progressing and non-progressing pregnancies were not statistically significant. In brief Although different routes of progesterone administration resulted in varying plasma levels on the day of embryo transfer (ET), these differences did not affect reproductive outcomes.